July 2007
Worldwide Biotech;Jul2007, Vol. 19 Issue 7, p4
Trade Publication
The article reports that the European Committee for Medicinal Products for Human Use has given a positive opinion on Mircera, a drug for the treatment of anemia associated with chronic kidney disease, from Roche. The committee recommends the granting of a marketing authorization for Mircera, an erythropoiesis-stimulating agent. The advantages of Mircera over other erythropoiesis-stimulating agents are outlined. An overview of the basis of the positive opinion is presented.


Related Articles

  • FDA approves Mircera for anemia.  // PharmaWatch: Biotechnology;Jan2008, Vol. 7 Issue 1, p11 

    The article reports on the approval of Roche's Mircera by the U.S. Food and Drug Administration (FDA) as a treatment for anemia in patients with chronic kidney disease (CKD). The drug is the only FDA-approved erythropoiesis-stimulating agent (ESA) to provide correction to anemia with...

  • Roche: Avastin continues to march on.  // PharmaWatch: Cancer;Aug2006, Vol. 5 Issue 8, p15 

    The article reports that Roche Pharmaceuticals has submitted a marketing authorization application to the European Medicines for Avastin in previously untreated advanced breast cancer. The European filing of Avastin for the first-line treatment of advanced breast cancer was based on results of...

  • OSI Pharmaceuticals/Roche: Tarceva faces competition in Japan.  // PharmaWatch: Cancer;Dec2007, Vol. 6 Issue 12, p14 

    The article announces that the drug Tarceva from OSI Pharmaceuticals and Roche Pharmaceutical has been approved in Japan for the treatment of non-small cell lung cancer. The drug is set to face stiff competition from AstraZeneca PLC Iressa. The approval is based on the positive results from...

  • Roche Holding AG's (Basel CHE) new drug for advanced melanoma, Zelboraf, on average helped patients with the deadly disease live for more than a year, according to data from a late-stage trial.  // MondayMorning;5/21/2012, Vol. 20 Issue 21, p1 

    The article informs that data from a late-stage trial found that Roche Holding AG's new drug for advanced melanoma, Zelboraf, help patients with the deadly disease to live for more than a year. It has been informed that the trial is a follow-up to a pivotal 675-patient Phase III study which was...

  • Roche Stays Persistent Despite Patent Ruling Favoring Amgen. Young, Donna // BioWorld Today;8/30/2007, Vol. 18 Issue 169, p1 

    The article reports on a case over whether F. Hoffmann-La Roche Limited's erythropoiesis-stimulating agent (ESA) Mircera infringes patents held by Amgen Inc. U.S. District Court Judge William G. Young in Massachusetts recently ruled that Mircera infringed Amgen's composition patent. Roche...

  • Genentech/Roche: Avastin back on track.  // PharmaWatch: Monthly Review;Mar2005, Vol. 4 Issue 3, p7 

    The article reports on the marketing approval issued by the European Union (EU) for the Avastin, a colorectal cancer treatment developed by Genentech Inc. and Roche Pharmaceuticals. The drug has been granted approval in the EU for the first-line treatment of colorectal cancer in combination with...

  • Roche target lung cancer with Avastin.  // Pharmaceutical Technology Europe;Oct2006, Vol. 18 Issue 10, p18 

    The article reports that Roche AG has submitted a marketing authorization application to the European Medicines Agency for the use of Avastin, an its anticancer therapy. The application seeks authorization for the use of the drug with chemotherapy in the treatment of non-small cell lung cancer...

  • Roche Grows Position in Japan.  // Chemical Market Reporter;12/22/2003, Vol. 264 Issue 22, p10 

    Reports on the expansion of operations of pharmaceutical company, Roche in Japan. Market trends; Drug launches and approvals; Business growth strategy by Roche; Licensing agreement signed by Chugai and Roche that will grant Chugai development and marketing rights in Japan for two cancer drugs.

  • Europe Approves Child-Sized Anti-Flu Medicine.  // Drug Discovery & Development;Oct2007, Vol. 10 Issue 10, p32 

    The article reports that the European Commission has approved the child-sized capsules for anti-flu drug Tamiflu from Roche Pharmaceuticals. It is stated that the lower dose capsules of 30mg and 45mg provide an alternative for treating and preventing influenza types A and B in children one year...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics